Menu
Search
|

Menu

Close
X

Vericel Corp VCEL.OQ (NASDAQ Stock Exchange Capital Market)

19.08 USD
-0.34 (-1.75%)
As of 1:23 PM EDT
Previous Close 19.42
Open 19.38
Volume 38,047
3m Avg Volume 164,849
Today’s High 19.51
Today’s Low 18.93
52 Week High 21.00
52 Week Low 9.60
Shares Outstanding (mil) 32.82
Market Capitalization (mil) 160.84
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.40 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
22
FY18
91
FY17
64
FY16
54
EPS (USD)
FY19
-0.065
FY18
-0.238
FY17
-0.532
FY16
-1.172
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.67
Price to Sales (TTM)
vs sector
2.99
7.92
Price to Book (MRQ)
vs sector
11.49
5.39
Price to Cash Flow (TTM)
vs sector
--
24.37
Total Debt to Equity (MRQ)
vs sector
72.73
14.56
LT Debt to Equity (MRQ)
vs sector
57.62
10.21
Return on Investment (TTM)
vs sector
-120.46
14.49
Return on Equity (TTM)
vs sector
--
15.79

EXECUTIVE LEADERSHIP

Robert Zerbe
Independent Chairman of the Board, Since 2012
Salary: --
Bonus: --
Dominick Colangelo
President, Chief Executive Officer, Director, Since 2014
Salary: $592,000.00
Bonus: $106,560.00
Gerard Michel
Chief Financial Officer, Vice President - Corporate Development, Since 2014
Salary: $386,000.00
Bonus: $46,320.00
Michael Halpin
Chief Operating Officer, Since 2019
Salary: --
Bonus: --
Steven Gilman
Independent Director, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

64 Sidney St
CAMBRIDGE   MA   02139-4170

Phone: +1734.9305555

Vericel Corporation is an integrated, commercial-stage biopharmaceutical company dedicated to the identification, development and commercialization of therapies that enable the body to repair and regenerate damaged tissues and organs to restore normal structure and function. The Company operates through the research, product development, manufacture and distribution of cellular therapies for use in the treatment of specific diseases.. Its autologous cell therapy products include Epicel (cultured epidermal autografts), which is a permanent skin replacement for the treatment of patients with deep-dermal or full-thickness burns. The Company is developing MACI, which is a third-generation autologous chondrocyte implant and ixmyelocel-T, which is a patient-specific multicellular therapy.

SPONSORED STORIES